Assay and Drug Development Technologies, Mary Ann Liebert Inc.

Assay and Drug Development Technologies Published by Mary Ann Liebert Inc. www.liebertpub.com/adt Widely circulated peer-reviewed journal focused specifically on the field of drug discovery and development.
Audience	Researchers and C Level Executives at pharmaceutical and biotech companies and academia
Frequency	6 issues a year: February, April, June, August, October & December
Editorial Focus	Early-stage screening techniques and tools that optimise the identification of novel leads and targets for new drug development Coverage includes: Assay design & target development High throughput technologies and chemistry Lab automation and sample management Data analysis and information management Bioinformatics, data mining, and virtual screening Biosensors and detection technologies Miniaturization, microfluidics, and nanotechnology Novel screening methods Metabolically engineered cells and organisms Imaging technologies Content includes original and review papers, interviews with researchers and innovators, new product and technology reviews, novel preliminary studies, literature citations and reviews, technology tutorials and dissertations focusing on cutting-edge research.
Editor(s) in Chief	Jim Inglese, Ph.D., NIH. New Products Editor Susan Jensen Tel +1 914 740 2100 sjensen@liebertpub.com
Print Advertising Options	Adverts, Inserts & Supplements
Digital Advertising Options	Banners on website Banners on subscriber Table of Contents email alerts
Further Information	Hilary Turnbull Tel: +44 (0) 1875 825 700 hturnbull@impressmedia.com
Publisher	Assay and Drug Development Technologies is owned and published by Mary Ann Liebert, Inc. Editorial headquarters: 140 Huguenot Street, New Rochelle, New York 10801, USA. Phone: +1 (914) 740-2100. Fax: +1 (914) 740-2101 www.liebertpub.com